[Development of new drugs for intractable vasculitis--lipo-PGE1 and monoclonal antibody].
"Lipo-PGE1", PGE1 incorporated into lipid microspheres (LM), has marked antiplatelet and vasodilatory actions. Since LM largely accumulate in inflamed vascular lesions, lipo-PGE1 shows a marked efficacy for treating vascular diseases such as atherosclerosis and vasculitis. Another recently developed drugs against intractable vasculitis are monoclonal antibodies to surface antigens of lymphocytes. Treatment with humanized anti-CDw52, and subsequent anti-CD4 monoclonal antibodies was reported to have brought remission up to 42 months.
Matsuda
T
T
Institute of Medical Science, St. Marianna University School of Medicine.
Hoshi
K
K
Igarashi
R
R
Ichikawa
Y
Y
D000527:Alprostadil / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology; D006801:Humans; D014657:Vasculitis / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000527:Alprostadil